OMERS ADMINISTRATION Corp Decreases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

OMERS ADMINISTRATION Corp cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 15,700 shares of the medical equipment provider's stock after selling 4,400 shares during the period. OMERS ADMINISTRATION Corp's holdings in Lantheus were worth $1,405,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in LNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Lantheus by 4.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,212 shares of the medical equipment provider's stock valued at $3,508,000 after purchasing an additional 1,531 shares during the last quarter. LRI Investments LLC grew its holdings in shares of Lantheus by 8.4% in the fourth quarter. LRI Investments LLC now owns 3,107 shares of the medical equipment provider's stock worth $278,000 after acquiring an additional 240 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in Lantheus during the fourth quarter valued at approximately $2,406,000. Janus Henderson Group PLC raised its position in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the period. Finally, Gotham Asset Management LLC boosted its stake in shares of Lantheus by 4.8% during the 4th quarter. Gotham Asset Management LLC now owns 12,905 shares of the medical equipment provider's stock worth $1,154,000 after acquiring an additional 596 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Trading Down 0.4%

Shares of NASDAQ:LNTH traded down $0.30 during trading on Wednesday, reaching $76.54. The company's stock had a trading volume of 279,805 shares, compared to its average volume of 981,210. The stock has a market capitalization of $5.30 billion, a PE ratio of 12.76 and a beta of 0.23. Lantheus Holdings, Inc. has a 12 month low of $75.00 and a 12 month high of $126.89. The firm's 50 day simple moving average is $96.20 and its two-hundred day simple moving average is $92.76.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the business earned $1.69 EPS. Research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LNTH has been the topic of several analyst reports. Truist Financial lowered their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. StockNews.com raised Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, B. Riley lowered their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $132.67.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock valued at $6,016,046 over the last three months. 1.50% of the stock is owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.